Trademark: 90596751
Word
CRISPR BY DESIGN
Status
Pending
Status Code
732
Status Date
Thursday, February 8, 2024
Serial Number
90596751
Mark Type
4000
Filing Date
Tuesday, March 23, 2021
Published for Opposition
Tuesday, June 21, 2022

Trademark Owner History
Scribe Therapeutics Inc. - Owner At Publication

Classifications
5 Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeuticsin the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders
44 Molecular diagnostic testing, monitoring and reporting services for medical purposes and medical research purposes; Medical diagnostic testing services in the field of human disease and human medical conditions
42 Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, diagnostic and therapeutic products and services; design and development of engineered cells for use in scientific research and drug discovery and development; Providing medical research and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering
"CRISPR"

Trademark Events
Feb 9, 2024
Notice Of Approval Of Extension Request E-Mailed
Feb 8, 2024
Sou Extension 3 Granted
Feb 8, 2024
Sou Extension 3 Filed
Feb 8, 2024
Sou Teas Extension Received
Aug 12, 2023
Notice Of Approval Of Extension Request E-Mailed
Aug 10, 2023
Sou Extension 2 Granted
Aug 10, 2023
Sou Extension 2 Filed
Aug 10, 2023
Sou Teas Extension Received
Feb 10, 2023
Notice Of Approval Of Extension Request E-Mailed
Feb 8, 2023
Sou Extension 1 Granted
Feb 8, 2023
Sou Extension 1 Filed
Feb 8, 2023
Sou Teas Extension Received
Aug 16, 2022
Noa E-Mailed - Sou Required From Applicant
Jun 21, 2022
Official Gazette Publication Confirmation E-Mailed
Jun 21, 2022
Published For Opposition
Jun 1, 2022
Notification Of Notice Of Publication E-Mailed
May 19, 2022
Approved For Pub - Principal Register
Apr 26, 2022
Teas/Email Correspondence Entered
Apr 26, 2022
Correspondence Received In Law Office
Apr 26, 2022
Teas Response To Office Action Received
Oct 28, 2021
Notification Of Non-Final Action E-Mailed
Oct 28, 2021
Non-Final Action E-Mailed
Oct 28, 2021
Non-Final Action Written
Oct 27, 2021
Assigned To Examiner
Jun 28, 2021
New Application Office Supplied Data Entered
Mar 26, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24